header image
Anthelmintics: From Discovery to Resistance
February 5th - 7th, 2014 ~ San Francisco, California
We apologize for any inconvenience, but we are pleased to announce that the Anthelmintics Conference is now full. We have no more space available in our San Francisco venue. We hope you'll attend a future conference and again, we apologize for any inconvenience if you wished to attend this year. Please email us at registrations@iastate.edu if you wish to be added to the mail list for notification when the upcoming conference is scheduled.

Aim: To review the current status of the discovery and development of new anthelmintic drugs, and to summarize recent progress in understanding how existing drugs work and how resistance to them arises.

The recent London Declaration on Neglected Tropical Diseases included statements committing signees to 'Sustain, expand and extend programmes that ensure the necessary supply of drugs and other interventions to help eradicate Guinea worm disease, and help eliminate by 2020 lymphatic filariasis....' and to 'Sustain, expand and extend drug access programmes to ensure the necessary supply of drugs and other interventions to help control by 2020 schistosomiasis, soil-transmitted helminths, ....and river blindness (onchocerciasis)'. Other important helminth diseases, such as food-borne trematodes and cysticercosis, affect tens of millions of people.

Many of these infections have been declared 'potentially eradicable' by the World Health Organisation and for some active elimination programs are under way. Except for Guinea worm, these are based on annual or more frequent mass administration of anthelmintic drugs, but there are major concerns for the implementation of these programs:

  1. Are the drugs currently available sufficient to allow these ambitious objectives to be achieved? If not, what alternatives are available?
  2. Do we know enough about the way these drugs work to use them in an optimal way?
  3. Intensive use of anthelmintic drugs in veterinary medicine has resulted in widespread resistance. How likely is this to occur in human medicine, what would the impact be and how can the risks be minimized?

There is an increasing consensus that new drugs will be needed if the goals of the London Declaration are to be met. This meeting is designed to address these issues in a way that promotes communication between those working in the medical and veterinary fields, and that brings together academic and industrial scientists working to discover and develop novel anthelmintic drugs.

We are delighted to acknowledge sponsorships from New England Biolabs, the Burroughs Wellcome Fund, and Zoetis for financial support for this conference.

Abstracts for poster and oral presentations are invited; the deadline for submission has been extended to November 22nd 2013.

Registration fees are $175, with a discounted rate of $100 for registered students. Registration after November 15th will be subject to a 'late fee' of $50.

The following speakers and topics are confirmed for the 2014 conference:
  • Dr James McKerrow, UCSF; Molecular Drug targets in Schistosome and Filarid Parasites
  • Dr Jennifer Keiser, Swiss Trop Med Inst. Tackling Trichuris: from bench to field
  • John Rogers, NIAID. NIAID drug development and clinical development resources
  • Clothilde Carlow, NEB The druggable genomes of Brugia malayi and its Wolbachia endosymbiont
  • Christine Mertens, Bayer Animal Health Bitter pills to new medicines - the animal health industry perspective
  • Makedonka Mitreva, Wash U. An integrated multi-omics approach empowers development of anthelmintic drugs.
  • Sara Lustigman, New York The involvement of Brugia malayi cathepsin-like cysteine proteases in the endosymbiotic interaction with Wolbachia
  • Cedric Neveu, INRA Tours. Investigating the acetylcholine receptor diversity in parasitic nematodes as potential targets for the development of novel anthelmintics.
  • Raffi Arioan, UCSD. Engineering food-grade bacteria with crystal proteins as mass cures for soil-transmitted helminths
  • Tim Geary, McGill. Repurposing flubendazole as a macrofilaricide
  • Richard Martin, Iowa State. Effects of the paraherquamide, derquantel, and the macrocyclic lactone, abamectin, on native and expressed receptors of nematodes
  • Robert Greenberg, UPenn. Roles of schistosome ABC multidrug transporters in parasite physiology, anthelmintic susceptibility, and modulation of host immune function.
  • Georg von Samson-Himmelstjerna, FU Berlin. Macrocyclic-resistance associated polymorphisms and functional analysis of P-glycoproteins from equine gastro-intestinal nematodes.
  • Roger Prichard, McGill. Reversing the order: Anthelmintic resistance, use and discovery. How knowledge of resistance mechanisms and genetics can inform better use of anthelmintics and guide development of new anthelmintics.
  • Anne Lespine, INRA Toulouse. Overcoming anthelmintic resistance by targeting ABC transporter detoxification pathway
  • Ray Kaplan, UGA. @Anthelmintic Resistance in Nematode Parasites of Animals is #BreakingBad, #HumansNext?
  • Jacqui Matthews, Moredun. Mitigating anthelmintic resistance in horse nematodes
  • Andrew Kotze, CSIRO, Australia Drug-efflux and target-site gene expression patterns in Haemonchus contortus larvae able to survive increasing concentrations of anthelmintics.
Links | Home | Top    
Iowa State University | University Extension
Registration Services
117 Printing and Publications
Ames, Iowa 50011
(515) 294-6222
Mnet, Copyright 2008, Iowa State University, (Ver: 2.2.2b)